

Table S1.A Demographic parameters

<u>Characteristic</u>	<u>Value</u>
Age	
Average	70.4
Maximum	89
Minimum	48
Median	70
Ethnicity	
Caucasian	59
Hispanic	1
African-American	19
Asian	2
Gender	
Male	41
Female	40

Table S1.B: Tumor characteristics

<u>Characteristic</u>	<u>Value</u>
Primary diagnosis code	
Upper lobe, bronchus or lung(162.3)	42
Middle lobe, bronchus or lung(162.4)	3
Lower lobe, bronchus or lung(162.5)	28
Bronchus and lung, unspecified(162.9)	8
Central tumor or not	
Central	23
Peripheral	58
Tumor size (cm)	
Average	2.4
Maximum	6
Minimum	1
Histology	
Adenocarcinoma	44
Squamous cell	22
Bronchoalveolar	2
Not biopsied	2
Poorly differentiated	2
Biopsied	9
Location	
RUL	27
RML	2
RLL	16
LUL	21
LLL	15
Stage	

IA	63
IB	18

Abbreviations: RUL: Right upper lobe; RML: Right middle lobe;
RLL: right lower lobe; LUL: Left upper Lobe; LLL: Left lower lobe;

Table S1.C Treatment parameters

<u>Characteristic</u>	<u>Value</u>
Number fractions	
Maximum	5
Minimum	1
Median	3
Dose per fraction (Gy)	
Maximum	34
Minimum	8
Median	16
BED (Gy)	
Maximum	200.5
Minimum	52.8
Median	140.8

Abbreviation – BED: biological equivalent dose

Table S1.D Pretreatment medicine

<u>Characteristic</u>	<u>Value</u>
Antiinflammatories	
No	77
Yes	4
Anitdiabetic	
No	79
Yes	2
Metformin	
No	78
Yes	3
Statin	
No	51
Yes	30
ACE inhibitor	
No	54
Yes	27
ASA	
No	50
Yes	31

Abbreviations -ACE inhibitor: Angiotensin-converting-enzyme inhibitor;
ASA: Acetylsalicylic acid.

Table S2 Effects of selected optimal clinical parameters

Clinical parameter	Value	Odds Ratio
Age	≥ 70	Reference
	<70	1.950
Ethnicity	Caucasion	Reference
	Black	3.195
Gender	Male	Reference
	Female	2.812
Central tumor or not	Peripheral	Reference
	Central	1.820
Tumor size	< 2.5	Reference
	≥ 2.5	1.466
Histology	Adenocarcinoma	Reference
	Squamous cell	1.086
Stage	IA	Reference
	IB	4.476
Fractions	3	Reference
	5	2.500
Dose per fraction	≥ 18	Reference
	<18	2.520
Antiinflammatories	No	Reference
	Yes	1.091
Anitdiabetic	No	Reference
	Yes	3.364
Metformin	Yes	Reference
	No	1.239
Statin	Yes	Reference
	No	1.037
ACE inhibitor	Yes	Reference
	No	1.504
ASA	Yes	Reference
	No	2.825